Skip to main content
Psyence Group Inc. logo

Psyence Group Inc. — Investor Relations & Filings

Ticker · PSYG ISIN · CA74449Q2053 LEI · 549300RPEOIVSD0MJC07 CSE Manufacturing
Open in API
Filings indexed 195 across all filing types
Latest filing 2023-03-31 Capital/Financing Update
Country CA Canada
Listing CSE PSYG

About Psyence Group Inc.

https://psyence.com/

Psyence Group Inc. is a science-led life science biotechnology company focused on the research, cultivation, and production of natural psychedelics and nature-based compounds. The company develops innovative, safe, and effective solutions for mental health. Its core clinical division, Psyence Therapeutics (now part of Psyence Biomedical Ltd.), pioneers the use of natural psilocybin formulations and treatment protocols, primarily targeting anxiety and depression within the context of palliative care. Supporting this effort, the company operates one of the world's first federally licensed, ISO22000 certified psilocybin cultivation and production facilities. Furthermore, Psyence Function markets a range of non-psychoactive functional mushroom wellness products utilizing adaptogens.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the closing of a tranche of a private placement and the conversion of a convertible debt note. It details the issuance of common shares, proceeds raised, and grants of restricted share units and stock options. There is no financial statement or comprehensive financial report included. The content focuses on financing activities and capital raising rather than reporting financial results or management discussion. Therefore, this document fits the category of Capital/Financing Update (CAP). The document length is 6895 characters, which is sufficient for a detailed announcement but does not constitute a full financial report.
2023-03-31 English
Material change report - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a Form 51-102F3 Material Change Report filed by Psyence Group Inc. It details a material change event involving the closing of a private placement financing, conversion of convertible debt into shares, and grants of restricted share units and stock options. The content focuses on capital raising activities, share issuance, and related corporate actions. There are no financial statements or comprehensive financial performance data typical of annual or interim reports. The document is not a simple announcement of a report but a detailed disclosure of a material change event related to financing and capital structure. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence level.
2023-03-31 English
Other.pdf
Regulatory Filings
2023-03-24 English
News release - English.pdf
Capital/Financing Update Classification · 100% confidence The document is a press release announcing a private placement financing by Psyence Group with Cantheon Capital. It details the terms of the subscription agreement, the amount of investment, the use of proceeds for clinical trials, and related operational triggers. There is no financial statement data, no regulatory certification, no voting results, no management or board changes, no earnings or annual report content. The document is clearly an update on capital raising activity and financing terms. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length and content confirm it is not a brief announcement or a report publication notice, but a substantive financing announcement.
2023-03-23 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing a partnership between Psyence Group Inc and iNGENū for conducting a clinical trial in Australia. It discusses the design and regulatory compliance of the clinical trial, the company's business focus, and forward-looking statements about the trial and drug development. There are no financial statements, earnings data, regulatory certifications, or voting results. The content is primarily a corporate announcement about a clinical trial partnership and future plans, not a financial report, management change, or regulatory filing. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is a general corporate announcement about a business development, which best fits under Regulatory Filings (RNS) as a miscellaneous announcement that does not fit other specific categories.
2023-03-21 English
Material change report - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a Form 51-102F3 Material Change Report filed by Psyence Group Inc. It announces the closing of a third tranche of a private placement, detailing the issuance of shares and the use of proceeds. The content focuses on a financing event (private placement of shares) and does not contain financial statements or detailed financial performance data. It is a regulatory filing related to capital raising activity but is not a full financial report or earnings release. Given the detailed description of the private placement and capital raising, the document fits best under Capital/Financing Update (CAP). The document length (7151 characters) and content confirm it is a substantive announcement rather than a brief notice or certification. Therefore, the classification is CAP with high confidence.
2023-03-03 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.